BNGONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Bionano Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.22−0.03 (-2.40%)
Close on Oct 19, 2026
- Market cap
- $14.09M
- P/E (TTM)
- –
- Dividend yield
- –
Bionano Genomics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 47.5%
- Operating margin
- -106.7%
- Net margin
- -106.6%
- Return on equity, FY2025
- -66.2%
Financial strength
- Current ratio
- 2.48
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 37.2%
Valuation
- P/E ratio
- –
- Price to sales
- 0.47
- Price to book
- 0.45
- Dividend yield
- –